Skip to main content
. 2021 Jan 12;13:1759720X20986734. doi: 10.1177/1759720X20986734

Figure 1.

Figure 1.

The findings of the Assessment of Spondyloarthrtis International Society-40 in clinical trials for the treatment of adalimumab,47 certolizumab,45 and etanercept44 at 12 weeks and that of golimumab,46 secukinumab,53 and ixekizumab11 at 16 weeks in patients with nr-axSpA. The certolizumab group had 400 mg certolizumab administered every 4 weeks, and the secukinumab group was a loading dose group.